<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: High proinsulin concentration may be a better predictor for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) mortality than insulin concentration </plain></SENT>
<SENT sid="1" pm="."><plain>Previous observations may have been confounded by <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance status or lack of precision because of high intraindividual variability </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the longitudinal relation of means of duplicate measurements of insulin and proinsulin with <z:hpo ids='HP_0000001'>all</z:hpo>-cause and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality in a population-based cohort taking <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance status into account </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: Fasting and post-75-g <z:chebi fb="105" ids="17234">glucose</z:chebi>-load (2-h) <z:chebi fb="105" ids="17234">glucose</z:chebi>, insulin, and proinsulin values were determined in duplicate on separate days in 277 participants with <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, 208 participants with impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, and 119 newly detected patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> of the Hoorn Study </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> and beta-cell function were estimated by homeostasis model assessment (HOMA-IR and HOMA-B, respectively), and the fasting proinsulin-to-insulin ratio was calculated </plain></SENT>
<SENT sid="5" pm="."><plain>Subjects were followed with respect to mortality until January 2003 </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Fasting proinsulin levels were significantly associated with <z:hpo ids='HP_0000001'>all</z:hpo>-cause and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality </plain></SENT>
<SENT sid="7" pm="."><plain>The hazard ratios (HRs) per increase in interquartile range adjusted for age and sex were 1.21 (95% CI 1.04-1.42) for <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality and 1.33 (1.06-1.66) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality </plain></SENT>
<SENT sid="8" pm="."><plain>Adjustment for <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance status and HOMA-IR did not substantially change the associations </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Fasting proinsulin was associated with <z:hpo ids='HP_0000001'>all</z:hpo>-cause and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> mortality, independent of <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance status and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and largely independent of other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> risk factors </plain></SENT>
<SENT sid="10" pm="."><plain>Proinsulin might play a role in the relationship between <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
</text></document>